The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 352:2133-2134 May 19, 2005 Number 20
NextNext

Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Mayer, S. A.
-PubMed Citation
To the Editor: The trial conducted by Mayer et al. (Feb. 24 issue),1 showing that recombinant activated factor VII (rFVIIa) is beneficial for treating acute intracerebral hemorrhage, for which treatment options are extremely limited, is very exciting. The trial showed a reduction in hematoma growth (the primary end point); however, it is the associated reduction in mortality that most likely will influence practitioners to use this therapy. Although patients in a deep coma (defined as a score of less than 6 on the Glasgow Coma Scale [GCS]), whose mortality rate is extremely high,2 were excluded from the trial, the ranges . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.